Drug Index


Mechanism :

Tiagabine is a nipecotic acid derivative that is used as an adjunct in the treatment of partial seizures. The exact mechanism not known but in vitro experiments show that it increases the activity of gamma aminobutyric acid (GABA) by binding to the GABA uptake carrier, thus inhibiting the uptake of GABA into presynaptic neurons, resulting in an increased amount of GABA to be available to postsynaptic neurons.

Indication :

  • Adjunct in refractory partial seizures.

Contraindications :

Discontinue treatment if there is sign of hypersensitivity. Hepatic impairment. Safety and efficacy have not been established in children <12 yr. Avoid abrupt withdrawal. Monitor for any sign/symptom (e.g. behaviour changes, anxiety, depression) of suicidal tendency or ideation. Pregnancy and lactation.

Dosing :

<12 Years:
Safety and efficacy is not established.
>12 Years:
4 mg every 12 hours for one week. Increase weekly by 4-8 mg. (Max dose: 32 mg/day) divided every 6-12 hours.

Adverse Effect :

CNS depression, dizziness, nervousness, somnolence. nausea, diarrhoea, abdominal pain, asthenia, tremor, weakness, chest pain, oedema, hypertension, palpitation, peripheral oedema, syncope, tachycardia, vasodilation.

Severe reactions: Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Interaction :

Sedative Drugs or Ethanol: Increased sedation when used with other sedative drugs or ethanol.

Valproate: May increase free tiagabine levels.

CYP3A4 inhibitors: Concurrent use with CYP3A4 inhibitors (e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin and verapamil) may increase levels of tiagabine. CYP3A4 inducers (e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin and rifamycin) may decrease levels of tiagabine.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Dosage reduction may be necessary since clearance is reduced in the setting of hepatic impairment.
03/18/2024 23:16:07 Tiagabine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0